| Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology OD Howes, R McCutcheon, O Agid, A De Bartolomeis, NJM Van Beveren, ... American Journal of Psychiatry 174 (3), 216-229, 2017 | 1057 | 2017 |
| Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder RM Bilder, RS Goldman, J Volavka, P Czobor, M Hoptman, B Sheitman, ... American Journal of Psychiatry 159 (6), 1018-1028, 2002 | 776 | 2002 |
| Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics JP Lindenmayer, P Czobor, J Volavka, L Citrome, B Sheitman, JP McEvoy, ... American Journal of Psychiatry 160 (2), 290-296, 2003 | 737 | 2003 |
| Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder J Volavka, P Czobor, B Sheitman, JP Lindenmayer, L Citrome, JP McEvoy, ... American Journal of Psychiatry 159 (2), 255-262, 2002 | 606 | 2002 |
| Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia RM Bilder, J Volavka, P ál Czobor, AK Malhotra, JL Kennedy, X Ni, ... Biological psychiatry 52 (7), 701-707, 2002 | 456 | 2002 |
| Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder MI Krakowski, P Czobor, L Citrome, N Bark, TB Cooper Archives of General Psychiatry 63 (6), 622-629, 2006 | 438 | 2006 |
| The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence CU Correll, L Citrome, PM Haddad, J Lauriello, M Olfson, SM Calloway, ... The Journal of clinical psychiatry 77 (suppl 3), 21984, 2016 | 395 | 2016 |
| Good publication practice for communicating company-sponsored medical research: GPP3 WP Battisti, E Wager, L Baltzer, D Bridges, A Cairns, CI Carswell, ... Annals of Internal Medicine 163 (6), 461-464, 2015 | 375 | 2015 |
| Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia L Citrome, J Volavka, P Czobor, B Sheitman, JP Lindenmayer, J McEvoy, ... Psychiatric Services 52 (11), 1510-1514, 2001 | 298 | 2001 |
| Antipsychotic-induced weight gain and therapeutic response: a differential association P Czobor, J Volavka, B Sheitman, JP Lindenmayer, L Citrome, J McEvoy, ... Journal of clinical psychopharmacology 22 (3), 244-251, 2002 | 271 | 2002 |
| When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed L Citrome, TA Ketter International journal of clinical practice 67 (5), 407-411, 2013 | 268 | 2013 |
| Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol J Volavka, P Czobor, K Nolan, B Sheitman, JP Lindenmayer, L Citrome, ... Journal of clinical psychopharmacology 24 (2), 225-228, 2004 | 255 | 2004 |
| Pathways to aggression in schizophrenia affect results of treatment J Volavka, L Citrome Schizophrenia bulletin 37 (5), 921-929, 2011 | 248 | 2011 |
| Heterogeneity of violence in schizophrenia and implications for long‐term treatment J Volavka, L Citrome International journal of clinical practice 62 (8), 1237-1245, 2008 | 229 | 2008 |
| An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels J De Leon, G Schoretsanitis, RL Smith, E Molden, A Solismaa, N Seppälä, ... Pharmacopsychiatry 55 (02), 73-86, 2022 | 221 | 2022 |
| Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. JP Lindenmayer, H Liu-Seifert, PM Kulkarni, BJ Kinon, V Stauffer, ... Journal of Clinical Psychiatry 70 (7), 990, 2009 | 208 | 2009 |
| Characteristics of assaultive behavior among psychiatric inpatients KA Nolan, P Czobor, BB Roy, MM Platt, CB Shope, LL Citrome, J Volavka Psychiatric services 54 (7), 1012-1016, 2003 | 207 | 2003 |
| Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update LM DeTora, D Toroser, A Sykes, C Vanderlinden, FJ Plunkett, T Lane, ... Annals of internal medicine 175 (9), 1298-1304, 2022 | 196 | 2022 |
| Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol J Volavka, P Czobor, TB Cooper, B Sheitman, JP Lindenmayer, L Citrome, ... Journal of Clinical Psychiatry 65 (1), 57-61, 2004 | 194 | 2004 |
| Compelling or irrelevant? Using number needed to treat can help decide L Citrome Acta Psychiatrica Scandinavica 117 (6), 412-419, 2008 | 190 | 2008 |